Track topics on Twitter Track topics that are important to you
The primary Objective of this study is to evaluate the safety and tolerability of intraocular injections of 0.5 or 2.0 mg of ranibizumab in patients with macular edema due to retinal vein occlusion.
The secondary objectives are to assess the bioactivity of 0.5 or 2.0 mg of ranibizumab in patients with macular edemas due to retinal vein occlusion by measuring the mean change from baseline in several parameters of visual function and retinal thickness at weeks 24 and 48. In addition, aqueous levels of cytokines and ranibizumab will be measured to assess for biomarkers of disease activity and response and to perform a pharmacodynamic analysis by correlating aqueous levels of ranibizumab with the above outcome measures. At week 24, patients will be re-randomized to receive laser photocoagulation to areas of capillary nonperfusion outside the fovea to assess the safety and tolerability of combination treatment with laser and ranibizumab.
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Retinal Vein Occlusion
Ranibizumab .5mg, Ranibizumab .5mg with laser, Ranibizumab 2.0 mg, Ranibizumab 2.o dose with laser
Wilmer Eye Institute at Johns Hopkins University
Johns Hopkins University
Published on BioPortfolio: 2010-07-15T17:00:00-0400
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with CNV seco...
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.
The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
This is a multicenter, randomized, open-label study. 30 patients will be followed for a period of 12 months. All consented and enrolled patients will receive 0.5mg of intravitreal ranibi...
The purpose of this study is to test the safety, tolerability and effectiveness of a higher dose (1.0 mg) of ranibizumab versus the standard dose (0.5 mg), in adults with age related macul...
Inflammatory optic disc neovascularisation (NVD) has been treated with periocular or systemic steroids, immunosuppressants, panretinal photocoagulation and bevacizumab. However, the role of intravitre...
The clinical efficacy of ranibizumab has been examined by a large number of prospective and retrospective studies to date. This meta-analysis was conducted to summarize the current body of evidence on...
Ranibizumab (Lucentis; Genentech, South San Francisco, CA) is used off-label for the treatment of choroidal neovascularization secondary to ocular histoplasmosis syndrome (OHS). This study prospective...
Case report of a patient with age-related macular degeneration whose digital ischemia can most plausibly be attributed to ranibizumab.
To analyze the efficacy of aflibercept switch treatment for regression of pigment epithelial detachment (PED) in patients previously treated with ranibizumab.
A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
A technique utilizing a laser coupled to a catheter which is used in the dilatation of occluded blood vessels. This includes laser thermal angioplasty where the laser energy heats up a metal tip, and direct laser angioplasty where the laser energy directly ablates the occlusion. One form of the latter approach uses an EXCIMER LASER which creates microscopically precise cuts without thermal injury. When laser angioplasty is performed in combination with balloon angioplasty it is called laser-assisted balloon angioplasty (ANGIOPLASTY, BALLOON, LASER-ASSISTED).
The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.
Techniques using laser energy in combination with a balloon catheter to perform angioplasty. These procedures can take several forms including: 1, laser fiber delivering the energy while the inflated balloon centers the fiber and occludes the blood flow; 2, balloon angioplasty immediately following laser angioplasty; or 3, laser energy transmitted through angioplasty balloons that contain an internal fiber.
Treatment using irradiation with LASER light of low power intensity so that the effects are not due to heat, as in LASER THERAPY. These non-thermal effects are thought to be mediated by a photochemical reaction that alters CELL MEMBRANE PERMEABILITY, leading to increased mRNA synthesis and CELL PROLIFERATION. Low-level laser therapy has been used for a wide variety of conditions, but most frequently for wound healing and pain control.